Robotic-assisted Exercise Training in Heart Failure

Status Completed

Clinical Trial Summary

Background: Regular physical activity is an evidence-based adjuvant therapy of chronic heart failure or chronic lung diseases. Structured exercise training is safe, increases exercise capacity and quality of life, relieves symptoms and reduces hospitalization rates. Even a trend towards reduction of mortality has been identified. However, dyspnea and fatigue, typical symptoms of heart or lung failure, force patients to physical inactivity which fatally aggravates deconditioning and exercise intolerance, leading to an increased risk of hospitalization and a loss of independence and quality of life. To break through this vicious circle physical activity must be restored, since exercise intolerance can be successfully improved by physical training. Purpose: This study will address the challenging task of remobilizing patients with advanced chronic lung or heart failure in a functional New York Heart Association class III-IV by using an externally physically-supported exosuit movement therapy. This soft, wearable robot (fig. 1) assists mobilization according to individual needs by activating neuromuscular feedback systems, promoting physical activity and preventing early physical exhaustion. The investigators hypotheses that an exosuit-supported training increases exercise capacity and quality of life in a greater degree than non-supported training. Methods: The study will consist of two parts investigating i) the feasibility, tolerance and safety (n= 30) and ii) the efficacy of an exosuit device-supported training (n=30). In i) patients will perform a walking test and a set of everyday life skills or participate in a standardized rehabilitation sports program. In ii) patients will be randomized in a 2:1 ratio for an exosuit-supported or non-supported exercise training protocol, training 3 units per week for 8 weeks. Assessment of outcome will be performed by various functional, mobility and endurance tests, questionnaires and clinical parameters. Furthermore, the transfer of regained motor and balance skills to everyday life will be analyzed.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04839133
Study type	Interventional
Source	German Heart Institute
Contact
Status	Completed
Phase	N/A
Start date	March 31, 2021
Completion date	July 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03572335` - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Recruiting	`NCT06088485` - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Terminated	`NCT03309358` - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis	Phase 1
Active, not recruiting	`NCT02504697` - DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer
Completed	`NCT01443845` - Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)	Phase 4
Terminated	`NCT00524095` - Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis	Phase 2
Completed	`NCT00210249` - Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Completed	`NCT00023114` - p450 Mediated Lung Toxicity	N/A
Recruiting	`NCT06056882` - Simultaneous CLE Guided Crybiopsy in Patients With Pulmonary Nodules
Completed	`NCT03994848` - Incentive Spirometry Prehabilitation Study	N/A
Completed	`NCT00366509` - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Withdrawn	`NCT05100160` - Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)	Phase 3
Completed	`NCT03229473` - Fall Risk Assessment in COPD
Recruiting	`NCT04767074` - A Non-pharmacological Cough Control Therapy	N/A
Not yet recruiting	`NCT03899298` - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions	Phase 1
Completed	`NCT04996693` - On Dose Efficiency of Modern CT-scanners in Chest Scans	N/A
Recruiting	`NCT04996173` - Cryospray Therapy Versus Standard of Care for Benign Airway Stenosis (CryoStasis)	N/A
Completed	`NCT04601545` - The Virtual Reality Therapy as a Pulmonary Rehabilitation Supporting Method	N/A
Recruiting	`NCT03937583` - Screening for Cancer in Patients With Unprovoked VTE	Phase 4
Recruiting	`NCT02862418` - Imaging of Lungs With a New Type of Magnetic Resonance Imaging (MRI) Called UTE (Ultrashort Echo Time)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.